Journal of Clinical and Aesthetic Dermatology

DEC 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/918586

Contents of this Issue

Navigation

Page 47 of 59

48 JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY December 2017 • Volume 10 • Number 12 O R I G I N A L R E S E A R C H work is the responsibility of the authors and does not necessarily represent the views of the CRO. This work was presented as an oral and poster presentation on April 28, 2017, at the 76th Annual Meeting of the Society for Investigative Dermatology in Portland, Oregon. REFERENCES 1. Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer. 2003;97(3):639 –643. 2. DiFronzo LA, Wanek LA, Elashoff R, Morton DL. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol. 1999;6(7):705 –711. 3. Francken AB, Bastiaannet E, Hoekstra HJ. Follow- up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6(8):608–621. 4. Trotter SC, Sroa N, Winkelmann RR, et al. A global review of melanoma follow-up guidelines. J Clin Aesthet Dermatol. 2013;6(9):18 –26. 5. Cromwell KD, Ross MI, Xing Y, et al. Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res. 2012;22(5):376 –385. 6. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology. Melanoma. Available at: http://www.nccn.org/ professionals/physician_gls/pdf/melanoma.pdf. Accessed October 2017. 7. Marciano NJ, Merlin TL, Bessen T, Street JM. To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence?. Int J Clin Pract. 2014;68(6):761 –770. 8. Slingluff CL,Jr, Vollmer RT, Seigler HF. Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery. 1993;113(3):330 –339. 9. Kang S, Barnhill RL, Mihm MC,Jr, et al. Multiple primary cutaneous melanomas. Cancer. 1992;70(7):1911 –1916. 10. Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA. 2005;294(13):1647 –1654. 11. Tas F, Erturk K. Recurrence behavior in early- stage cutaneous melanoma: pattern, timing, survival, and influencing factors. Melanoma Res. 2017;27(2):134 –139. 12. Sohi N, Davis SA. Impact of nonadherence in dermatology. In: Davis SA, ed. Adherence in Dermatology. Switzerland: Springer International Publishing; 2016: 3 –6. 13. Carlsen KH, Carlsen KM, Serup J. Non- attendance, predictors, and interventions. In: Davis SA, ed. Adherence in Dermatology. Switzerland: Springer International Publishing; 2016: 29 –38. 14. McKenna DB, Marioni JC, Lee RJ, et al. A comparison of dermatologists', surgeons' and general practitioners' surgical management of cutaneous melanoma. Br J Dermatol. 2004;151(3):636 –644. 15. Kalimullah FA, Brown CW. Compliance with follow-up among patients with melanoma and non-melanoma skin cancers. Dermatol Online J. 2014;20(2). pii: doj_21537. 16. Kittler H, Weitzdorfer R, Pehamberger H, et al. Compliance with follow-up and prognosis among patients with thin melanomas. Eur J Cancer. 2001;37(12):1504 –1509. 17. Holterhues C, van de Poll-Franse LV, de Vries E, et al. Melanoma patients receive more follow-up care than current guideline recommendations: a study of 546 patients from the general Dutch population. J Eur Acad Dermatol Venereol. 2012;26(11):1389 –1395. 18. Damude S, Hoekstra-Weebers JE, Francken AB, et al. The MELFO-study: prospective, randomized, clinical trial for the evaluation of a stage-adjusted reduced follow-up schedule in cutaneous melanoma patients-results after 1 year. Ann Surg Oncol. 2016;23(9):2762 –2771. 19. Scally CP, Wong SL. Intensity of follow-up after melanoma surgery. Ann Surg Oncol. 2014;21(3):752 –757. 20. National Cancer Institute. Melanoma of the Skin: Cancer Stat Facts. Available at: https://seer. cancer.gov/statfacts/html/melan.html. Accessed October 2017. 21. Lin AY, Wang PF, Li H, Kolker JA. Multicohort model for prevalence estimation of advanced malignant melanoma in the USA: an increasing public health concern. Melanoma Res. 2012;22(6):454 –459. 22. Livingstone E, Krajewski C, Eigentler TK, et al. Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study. Eur J Cancer. 2015;51(5):653 –667. 23. Bhutiani N, Egger ME, McMasters KM. Optimizing follow-up sssessment of patients with cutaneous melanoma. Ann Surg Oncol. 2017;24(4):861 – 863. 24. Wang C, Chen V, Vu V, et al. Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B. Medicine (Baltimore). 2016;95(35):e4744. 25. Singal AG, Yopp A, S Skinner C, et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012;27(7):861 –867. 26. Hamman MK, Kapinos KA. Affordable Care Act provision lowered out-of-pocket cost And increased colonoscopy rates among men in Medicare. Health Aff (Millwood). 2015;34(12):2069 –2076. 27. Cheah LP, Hemingway DM. Improving colorectal cancer follow-up: the dedicated single-visit colorectal cancer follow-up clinic. Ann R Coll Surg Engl. 2002;84(4):260 –262. 28. Tan AS, Moldovan-Johnson M, Parvanta S, et al. Patient-clinician information engagement improves adherence to colorectal cancer surveillance after curative treatment: results from a longitudinal study. Oncologist. 2012;17(9):1155 –1162. JCAD

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - DEC 2017